language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform
  1. Home
  2. Therakos Institute
  3. Speaker Meetings
TKS Institute TM CMYK 2022 WTE

Our Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Our speaker meetings help healthcare professionals stay up-to-date with the latest scientific knowledge and advancements in clinical practice across all clinical applications.

 

If you would like to receive more information, please contact your local sales representative. 

  • Upcoming Meetings
  • Past Meetings

Jun 1, 2023

Nordic Photopheresis Meeting Management of CLAD

Gothenburg, Sweden

Apr 6, 2023

CLAD and ECP: the Vienna experience

Strasbourg, France

Apr 5, 2023

CLAD and ECP: the Vienna experience

Lyon, France

Apr 4, 2023

CLAD and ECP: the Vienna experience

Nantes, France

Centres Excellence V2

Centres of Excellence

Centres of Excellence

Our Webinars Feature Image

Webinars

Webinars

Symposia V2

Symposia

Symposia

Rectangle 204 (1)

Ask the Expert

Ask the Expert

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?